These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26261585)

  • 21. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
    Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
    Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
    Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
    Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic impact of NDRG2 and NDRG3 in prostate cancer patients undergoing radical prostatectomy.
    Ren GF; Tang L; Yang AQ; Jiang WW; Huang YM
    Histol Histopathol; 2014 Apr; 29(4):535-42. PubMed ID: 24222185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions.
    Miyai K; Divatia MK; Shen SS; Miles BJ; Ayala AG; Ro JY
    Int J Clin Exp Pathol; 2014; 7(5):2518-26. PubMed ID: 24966964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of RABEX-5 and its clinical significance in prostate cancer.
    Zhang H; Cheng S; Wang A; Ma H; Yao B; Qi C; Liu R; Qi S; Xu Y
    J Exp Clin Cancer Res; 2014 Apr; 33(1):31. PubMed ID: 24716822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive factors associated with biochemical recurrence following radical prostatectomy for pathological T2 prostate cancer with negative surgical margins.
    Aoun F; Albisinni S; Henriet B; Tombal B; Van Velthoven R; Roumeguère T
    Scand J Urol; 2017 Feb; 51(1):20-26. PubMed ID: 27910728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The relationship between the extent of extraprostatic extension and survival following radical prostatectomy.
    Jeong BC; Chalfin HJ; Lee SB; Feng Z; Epstein JI; Trock BJ; Partin AW; Humphreys E; Walsh PC; Han M
    Eur Urol; 2015 Feb; 67(2):342-6. PubMed ID: 24968968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy: a Bayesian model averaging approach.
    Lee JY; Kang HW; Rha KH; Cho NH; Choi YD; Hong SJ; Cho KS
    J Cancer Res Clin Oncol; 2016 Apr; 142(4):849-58. PubMed ID: 26660495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
    Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
    Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of tumor-associated macrophages in the Hexim1 and TGFβ/SMAD pathway, and their influence on progression of prostatic adenocarcinoma.
    Ok Atılgan A; Özdemir BH; Akçay EY; Ataol Demirkan Ö; Tekindal MA; Özkardeş H
    Pathol Res Pract; 2016 Feb; 212(2):83-92. PubMed ID: 26608417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
    Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
    Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
    Guan Y; Wu Y; Liu Y; Ni J; Nong S
    Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.
    Epstein JI; Zelefsky MJ; Sjoberg DD; Nelson JB; Egevad L; Magi-Galluzzi C; Vickers AJ; Parwani AV; Reuter VE; Fine SW; Eastham JA; Wiklund P; Han M; Reddy CA; Ciezki JP; Nyberg T; Klein EA
    Eur Urol; 2016 Mar; 69(3):428-35. PubMed ID: 26166626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
    Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
    Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.
    Godtman RA; Holmberg E; Khatami A; Stranne J; Hugosson J
    Eur Urol; 2013 Jan; 63(1):101-7. PubMed ID: 22980443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perineural invasion by prostate cancer on MR/US fusion targeted biopsy is associated with extraprostatic extension and early biochemical recurrence after radical prostatectomy.
    Truong M; Rais-Bahrami S; Nix JW; Messing EM; Miyamoto H; Gordetsky JB
    Hum Pathol; 2017 Aug; 66():206-211. PubMed ID: 28705708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
    Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
    Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modification of the pT2 substage classification in prostate adenocarcinoma.
    Ettel M; Kong M; Lee P; Zhou M; Melamed J; Deng FM
    Hum Pathol; 2016 Oct; 56():57-63. PubMed ID: 27251951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
    Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
    World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.